[{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ AC Immune"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Inapplicable"}]

Find Neurology Drugs in Phase I Clinical Development in AUSTRIA

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

                          Product Name : PD01

                          Product Type : Vaccine

                          Upfront Cash : $5.0 million

                          July 27, 2021

                          Lead Product(s) : PD01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : AC Immune

                          Deal Size : $100.8 million

                          Deal Type : Acquisition

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.

                          Product Name : PD01

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 27, 2020

                          Lead Product(s) : PD01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank